. 2020 Dec 5;16(3):905–914. doi: 10.1016/j.jds.2020.09.015

Table 2.

The Mean and p values for: osteoclast cells, measurement of bone loss and PDL width, level of IL1 beta and RANKL expression and, Probing depth (median) in each group of the study.

Groups	Osteoclast cell count	Alveolar bone loss	PDL width	IL-1β (pg/μl)	RANKL (pg/μl)	Probing depth
Normal healthy (P value; Normal healthy vs EPD)	0.000 (0.0001)^a	6.21 ± 0.08 (0.0001)^a	19.06 ± 1.13 (0.0001)^a	1543.33 ± 194.21 (0.0001)^a	210 ± 19.32 (0.0001)^a	0.5 (0.0001)^b
EPD (P value; EPD vs CHX -T-EPD)	4.33 ± 0.84 (0.0001)^a	8.80 ± 0.42 (0.0001)^a	29.08 ± 2.05 (0.002)^a	8666.66 ± 299.62 (0.0001)^a	514.16 ± 44.35 (0.001)^a	3 (0.002)^b
CHX-T-EPD (P value; CHX -T-EPD vs Cu-T-EPD)	1.16 ± 0.47 (0.826)^a	7.00 ± 0.11 (0.532)^a	20.79 ± 2.00 (0.905)^a	4400 ± 288.67 (0.612)^a	343.33 ± 21.55 (0.591)^a	1 (0.132)^b
Cu-T-EPD (P value; Cu-T-EPD vs EPD)	1.33 ± 0.42 (0.001)^a	7.21 ± 0.16 (0.0001)^a	20.51 ± 1.03 (0.001)^a	4230 ± 81.44 (0.0001)^a	320 ± 29.09 (0.0001)^a	1 (0.002)^b

Within each row, values expressed by Mean ± SE, and P values, P ≤ 0.05 considered as significant.

PDL, Periodontal ligament width; IL-1β, Interleukin 1 beta; RANKL, receptor activator of nuclear factor kappa beta ligand; pg/μl, picograms/microliters; EPD, Experimental periodontitis; CHX-T-EPD, Chlorhexidine treated experimental periodontitis; Cu-T-EPD, Curcumin treated experimental periodontitis.

One-way ANOVA-LSD.

Mann–Whitney Test.